Transcranial Direct Current Stimulation in Conjunction With Individualized Physical Therapy for Individuals With Chronic Knee Pain

May 8, 2026 updated by: Sangeetha Madhavan, University of Illinois at Chicago
Background: There is a high prevalence of chronic pain in the US, with nearly half of adults experiencing chronic pain. Chronic pain is associated with impaired mobility, specifically ambulation. Treatment for chronic knee pain is complex given that pain is not only due to peripheral sources, but also due to alterations of the central nervous system (CNS). Majority of physical therapy (PT) interventions involve a bottom-up approach targeting the peripheral pain sources and many patients (~66%) do not respond to this treatment approach. Noninvasive brain stimulation techniques such as transcranial direct current stimulation (tDCS) is a novel and promising option for a top-down intervention that can have neuromodulatory effects on the CNS and may better target central factors associated with chronic pain. Purpose: To determine if tDCS delivered to the primary motor cortex in conjunction with individualized PT will result in greater improvements in pain and function compared to sham tDCS with individualized PT in individuals with chronic knee pain. Methods: This study will be performed at outpatient PT clinics at the University of Illinois Hospital. Eligible participants will include patients with chronic knee pain (duration > 3 months) who have not undergone surgery to this area and are scheduled to receive formal PT intervention. Subjects will be randomized to the active tDCS + PT group or sham tDCS + PT group and will receive the intervention for 8 sessions. Outcomes include pain ratings, pressure pain thresholds, patient specific functional scale, lower extremity functional scale, quadriceps strength, knee range of motion, 2-minute walk test, 5 time sit to stand, patient health questionnaire-2, and Central Sensitization Inventory. Impact: The use of adjuvant therapies such as tDCS have the potential to optimize rehabilitation treatment for individuals with chronic pain by offering a more comprehensive treatment that targets peripheral and central sources of pain.

Study Overview

Status

Active, not recruiting

Conditions

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Illinois
      • Chicago, Illinois, United States, 60612
        • University of Illinois Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age >/= 18 years old
  • Knee pain
  • Knee pain duration >/= 3 months

Exclusion Criteria:

General exclusion criteria

  • History of surgery on affected knee
  • Pregnant

tDCS exclusion criteria

  • Skin hypersensitivity
  • History of contact dermatitis
  • Any other skin or scalp condition that could be aggravated by tDCS
  • Previous adverse reactions to tDCS

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: active tDCS+PT
For those participants assigned to the active or sham tDCS groups, the overall set-up will be identical between groups and will use the Mini-CT device. However, the sham tDCS group will have the tDCS device turned off after 30 seconds of stimulation. Saline-soaked sponge electrodes that are 35 cm^2 in size will be used for both the active and sham tDCS groups. For electrode placement, the active electrode (anode) will be placed over M1 contralateral to the side of primary knee pain (over C3/4 using the 10-20 system for electrode placement), while the reference electrode (cathode) will be over the contralateral supraorbital region, which is ipsilateral to the painful knee (Fp2 using the 10-20 system). The intensity will be set at 2mA for the active tDCS group, following a 30 second ramp-up time. The participants in the active tDCS group will undergo 20 minutes of tDCS treatment prior to receiving individualized PT intervention.
Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that can have neuromodulatory effects on central nervous system structures, specifically the primary motor cortex (M1), and can potentially target maladaptive plasticity and nociplastic sources of pain. There is both anodal and cathodal tDCS, anodal stimulation increases excitability of the cortex whereas cathodal stimulation decreases excitability. At the synaptic level, anodal tDCS induces effects that mimic long term potentiation (LTP), while cathodal tDCS results in long term depression.
Other Names:
  • tDCS
Participants will receive individualized and impairment-based physical therapy treatment for their knee pain. This treatment can involve manual therapy, exercise or balance training depending on their particular needs.
Other Names:
  • PT
Sham Comparator: sham tDCS+PT
For those participants assigned to the active or sham tDCS groups, the overall set-up will be identical between groups and will use the Mini-CT tDCS device. However, the sham tDCS group will have the tDCS device turned off after 30 seconds of stimulation. Saline-soaked sponge electrodes that are 35 cm^2 in size will be used for both the active and sham tDCS groups. For electrode placement, the active electrode (anode) will be placed over M1 contralateral to the side of primary knee pain (over C3/4 using the 10-20 system for electrode placement), while the reference electrode (cathode) will be over the contralateral supraorbital region, which is ipsilateral to the painful knee (Fp2 using the 10-20 system). The participants in the sham tDCS group will undergo 20 minutes of sham tDCS treatment prior to receiving individualized PT intervention.
Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that can have neuromodulatory effects on central nervous system structures, specifically the primary motor cortex (M1), and can potentially target maladaptive plasticity and nociplastic sources of pain. There is both anodal and cathodal tDCS, anodal stimulation increases excitability of the cortex whereas cathodal stimulation decreases excitability. At the synaptic level, anodal tDCS induces effects that mimic long term potentiation (LTP), while cathodal tDCS results in long term depression.
Other Names:
  • tDCS
Participants will receive individualized and impairment-based physical therapy treatment for their knee pain. This treatment can involve manual therapy, exercise or balance training depending on their particular needs.
Other Names:
  • PT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recruitment ratio
Time Frame: through study completion, an average of 1 year
We will record the number of patients screened and enrolled in the study.
through study completion, an average of 1 year
Pain (NPRS)
Time Frame: baseline, every follow-up session through study completion
This will be measured subjectively using the Numeric Pain rating scale (NPRS). The PT or key research personnel with ask the participant their pain rating using a 0-10 scale. They will ask the current pain intensity rating, highest and lowest pain intensity rating in the past 2 week period.
baseline, every follow-up session through study completion
Two-minute walk test (2MWT)
Time Frame: baseline, at final intervention session
Distance walked, number of rest breaks and the assistive device(s) used during a 2MWT will be measured. From this test walking speed can also be calculated.
baseline, at final intervention session

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pressure pain threshold (PPT)
Time Frame: baseline, at final intervention session
PPT will be obtained with an electronic pressure algometer and the pressure will be recorded in kPa to allow for comparison to norms
baseline, at final intervention session
central sensitization inventory (CSI)
Time Frame: baseline, at final intervention session
CSI is a self-report questionnaire that will be used as a secondary outcome to identify patients that may have symptoms related to central sensitization or nociplastic pain which may allow for subgroup analysis of data to occur
baseline, at final intervention session
Lower extremity functional scale (LEFS)
Time Frame: baseline, at final intervention session
self-report questionnaire where participants will rate the difficulty level they have with various daily mobility tasks
baseline, at final intervention session
Patient specific functional scale (PSFS)
Time Frame: baseline, at final intervention session
The PSFS is a self-report outcome measure that is individualized to the patient's specific activity impairments. The participant will choose 3 activities that are limited or difficult for them due to their knee pain and then will rate the level of difficulty of each task. On this scale, 0 means that the participant is unable to complete the activity at all and 10 means that the participant is able to perform the activity at the same level as before the injury or problem.
baseline, at final intervention session
Five time sit to stand (5STS)
Time Frame: baseline, at final intervention session
5STS will time the amount of time it takes for the participant to stand up and sit down five times as fast as they can from a standard chair without the use of their upper extremities if possible. If participants require upper extremity support to complete the task then this will be documented
baseline, at final intervention session
knee range of motion (ROM)
Time Frame: baseline, at final intervention session
): Knee flexion and extension ROM will be measured with the patient in a supine position if possible. If participants have knee ROM measured in a position other than supine this will be documented.
baseline, at final intervention session
quadriceps strength
Time Frame: baseline, at final intervention session
Quadriceps strength will be assessed using a hand-held dynamometer with the patient in a seated position
baseline, at final intervention session
Treatment adherence
Time Frame: through study completion, an average of 1 year
Adherence to tDCS and physical therapy treatment will also be recorded.
through study completion, an average of 1 year
tDCS satisfaction
Time Frame: at final intervention session
Participants and clinicians involved in the study will also complete a survey following completion of the study regarding their impressions (positive and negative) regarding tDCS.
at final intervention session

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 6, 2024

Primary Completion (Actual)

December 1, 2025

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

October 30, 2023

First Submitted That Met QC Criteria

November 9, 2023

First Posted (Actual)

November 15, 2023

Study Record Updates

Last Update Posted (Actual)

May 11, 2026

Last Update Submitted That Met QC Criteria

May 8, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Knee Pain Chronic

Clinical Trials on transcranial direct current stimulation

Subscribe